A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE� Antibody Blinatumomab in Adult Subjects with Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)

To evaluate the rate of complete remission/complete remission with partial hematological recovery (CR/CRh*) in adult subjects with Relapsed/Refractory (R/R) Philadelphia Chromosome Positive (Ph+) B-precursor Acute Lymphoblastic Leukemia (ALL) who receive blinatumomab